search
Back to results

Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Primary Purpose

Breast Cancer Stage IV

Status
Not yet recruiting
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Huaier Granule
Sponsored by
Fudan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer Stage IV focused on measuring non-visceral metastasis, Huaier granule, randomized controlled, prospective clinical study

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18 years old ≤ age ≤ 75, regardless of gender. For breast cancer patients who are clinically or pathologically diagnosed as non visceral metastasis, if the patient has only local recurrence or metastasis, the clinician judges that it is not suitable or refuses to use local treatment with radical intensity, such as surgical resection or radiotherapy. Prior to enrollment, no more than first-line chemotherapy/endocrine therapy/targeted therapy/immunotherapy were allowed;If the patient has previously received first-line therapy, the outcome of treatment should be clinically assessed as disease progression or intolerance. There is at least one measurable lesion that meets the RECIST 1.1 standard, or only bone metastases (including osteolytic lesions or mixed lesions). The liver and kidney functions meet the following conditions: AST and ALT<3 ULN, total bilirubin ≤ 2 ULN, and blood creatinine<1.5 ULN. Other laboratory tests meet the following requirements: Hb ≥ 9g/dl, platelet count ≥ 60 × 10^9/L, absolute neutrophil count>1.0 × 10^9/L. Expected survival time ≥ 12 weeks. The patient's ECOG physical state score is 0 or 1. The subjects participated in the study voluntarily and signed an informed consent form. Exclusion Criteria: Any other malignancies diagnosed within 5 years prior to enrollment, except those with a low risk of metastasis and death (5-year survival > 90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ. There is visceral metastasis of breast cancer. Patients with advanced (local recurrence or metastasis) breast cancer who plan to receive radical local treatment. Serious infections (CTCAE>Level 2) have occurred within 4 weeks prior to enrollment, such as severe pneumonia, bacteremia, infection complications that require hospitalization; Symptoms and signs of infection or the need for oral or intravenous antibiotic treatment within 2 weeks prior to enrollment, except for prophylactic use of antibiotics. Suffering from severe acute and chronic diseases. Suffering from severe diabetes whose blood sugar cannot be effectively controlled. Patients who cannot take oral medication or are allergic to the ingredients of Huaier granules. Drug abusers, or those who suffer from psychological or mental illnesses that may interfere with research compliance. Pregnant or lactating women. The researcher believes that it is not suitable to participate in this study.

Sites / Locations

  • The Fourth Hospital of Hebei Medical University
  • The First Affiliated Hospital of Zhengzhou University
  • The First Hospital of Hunan University of Chinese Medicine
  • The Third Xiangya Hospital of Central South University
  • Nantong First People's Hospital
  • Northern Jiangsu People's Hospital
  • The International Peace Maternity & Child Health Hospital of China welfare institute
  • Fudan University Shanghai Cancer Center
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
  • Zhejiang Cancer Hospital
  • The First Hospital of Jiaxin
  • Lishui Municipal Central Hospital
  • Taizhou Central Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Huaier Granule+Standard treatment

Standard treatment

Arm Description

The subject is administered according to the clinical dosage and method of medication until disease progression occurs or the subject is unable to tolerate treatment.Subjects receiving routine diagnosis and treatment simultaneously.

Subjects receive routine diagnosis and treatment without taking Huaier granules.

Outcomes

Primary Outcome Measures

Investigator evaluated progression free survival
The time from randomization to the first occurrence of disease progression or death from any cause. As long as the subject experiences either "disease progression" or "death" first, it reaches the endpoint of the study

Secondary Outcome Measures

Overall survival(OS)
The time from randomization to death (from any cause)
Clinical benefit rate (CBR)
The percentage of patients with advanced breast cancer who achieved a complete response, partial response, or stable disease for at least six months after treatment
Objective response rate (ORR)
Proportion of patients whose breast cancer has shrunk to a predetermined volume and maintains a minimum time limit
Adverse reactions
Harmful reactions of Huaier granules that are unrelated to the purpose of the medication under normal usage and dosage

Full Information

First Posted
May 5, 2023
Last Updated
September 22, 2023
Sponsor
Fudan University
Collaborators
LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT05860907
Brief Title
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
Official Title
A Multicenter, Open-label, Randomized, Controlled, Prospective Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
October 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fudan University
Collaborators
LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, open-label, randomized controlled, prospective clinical study to evaluate the efficacy and safety of Huaier Granules in patients with advanced breast cancer without visceral metastasis.
Detailed Description
This study used a blank control design and included at least 384 subjects. The experimental group and control group were randomized in a 2:1 ratio (at least 256 subjects in the experimental group and at least 128 subjects in the control group). Patients in the experimental group were treated with Huaier Granules (10g/dose, 3 times/day), while undergoing routine diagnosis and treatment; The control group received routine diagnosis and treatment, but did not take Huaier granules until the subjects experienced disease progression or intolerance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer Stage IV
Keywords
non-visceral metastasis, Huaier granule, randomized controlled, prospective clinical study

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
384 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Huaier Granule+Standard treatment
Arm Type
Experimental
Arm Description
The subject is administered according to the clinical dosage and method of medication until disease progression occurs or the subject is unable to tolerate treatment.Subjects receiving routine diagnosis and treatment simultaneously.
Arm Title
Standard treatment
Arm Type
No Intervention
Arm Description
Subjects receive routine diagnosis and treatment without taking Huaier granules.
Intervention Type
Drug
Intervention Name(s)
Huaier Granule
Other Intervention Name(s)
Z20000109(NMPA Approval Number)
Intervention Description
10g each time, three times a day
Primary Outcome Measure Information:
Title
Investigator evaluated progression free survival
Description
The time from randomization to the first occurrence of disease progression or death from any cause. As long as the subject experiences either "disease progression" or "death" first, it reaches the endpoint of the study
Time Frame
start of treatment until 3.5-year follow-up
Secondary Outcome Measure Information:
Title
Overall survival(OS)
Description
The time from randomization to death (from any cause)
Time Frame
start of treatment until 3.5-year follow-up
Title
Clinical benefit rate (CBR)
Description
The percentage of patients with advanced breast cancer who achieved a complete response, partial response, or stable disease for at least six months after treatment
Time Frame
start of treatment until 3.5-year follow-up
Title
Objective response rate (ORR)
Description
Proportion of patients whose breast cancer has shrunk to a predetermined volume and maintains a minimum time limit
Time Frame
start of treatment until 3.5-year follow-up
Title
Adverse reactions
Description
Harmful reactions of Huaier granules that are unrelated to the purpose of the medication under normal usage and dosage
Time Frame
start of treatment until 3.5-year follow-up
Other Pre-specified Outcome Measures:
Title
Reduction rate of immune-related cytokines
Description
During the treatment process, the decrease rate of immune related cytokines(Such as IL-1 β, IL-2,IL-4,IL-5,IL-6,IL-8,IL-10,IL-12,IL-17,TNF- α, IFN- α, IFN- γ etc.) compared to the baseline period
Time Frame
The baseline period,12th week±14 days and 168th week±14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years old ≤ age ≤ 75, regardless of gender. For breast cancer patients who are clinically or pathologically diagnosed as non visceral metastasis, if the patient has only local recurrence or metastasis, the clinician judges that it is not suitable or refuses to use local treatment with radical intensity, such as surgical resection or radiotherapy. Prior to enrollment, no more than first-line chemotherapy/endocrine therapy/targeted therapy/immunotherapy were allowed;If the patient has previously received first-line therapy, the outcome of treatment should be clinically assessed as disease progression or intolerance. There is at least one measurable lesion that meets the RECIST 1.1 standard, or only bone metastases (including osteolytic lesions or mixed lesions). The liver and kidney functions meet the following conditions: AST and ALT<3 ULN, total bilirubin ≤ 2 ULN, and blood creatinine<1.5 ULN. Other laboratory tests meet the following requirements: Hb ≥ 9g/dl, platelet count ≥ 60 × 10^9/L, absolute neutrophil count>1.0 × 10^9/L. Expected survival time ≥ 12 weeks. The patient's ECOG physical state score is 0 or 1. The subjects participated in the study voluntarily and signed an informed consent form. Exclusion Criteria: Any other malignancies diagnosed within 5 years prior to enrollment, except those with a low risk of metastasis and death (5-year survival > 90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ. There is visceral metastasis of breast cancer. Patients with advanced (local recurrence or metastasis) breast cancer who plan to receive radical local treatment. Serious infections (CTCAE>Level 2) have occurred within 4 weeks prior to enrollment, such as severe pneumonia, bacteremia, infection complications that require hospitalization; Symptoms and signs of infection or the need for oral or intravenous antibiotic treatment within 2 weeks prior to enrollment, except for prophylactic use of antibiotics. Suffering from severe acute and chronic diseases. Suffering from severe diabetes whose blood sugar cannot be effectively controlled. Patients who cannot take oral medication or are allergic to the ingredients of Huaier granules. Drug abusers, or those who suffer from psychological or mental illnesses that may interfere with research compliance. Pregnant or lactating women. The researcher believes that it is not suitable to participate in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhimin Shao, PhD
Phone
+8618017312288
Email
zhimingshao@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Liang Huang, PhD
Phone
+8618121299334
Email
fdhlyx@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhimin Shao, Professor
Organizational Affiliation
Fudan University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Fourth Hospital of Hebei Medical University
City
Shijia Zhuang
State/Province
Hebei
ZIP/Postal Code
050011
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Ma, PhD
Phone
+8613932116886
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xin Ge, PhD
Phone
+8613303719081
Facility Name
The First Hospital of Hunan University of Chinese Medicine
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410011
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinhui Hu, PhD
Phone
+8613637412178
Facility Name
The Third Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Boni Ding, PhD
Phone
+8613627418663
Facility Name
Nantong First People's Hospital
City
Nantong
State/Province
Jiangsu
ZIP/Postal Code
226006
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinpeng Chen, PhD
Phone
+8618551315594
Facility Name
Northern Jiangsu People's Hospital
City
Yangzhou
State/Province
Jiangsu
ZIP/Postal Code
225001
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deyuan Fu, PhD
Phone
+8618051060677
Facility Name
The International Peace Maternity & Child Health Hospital of China welfare institute
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200030
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Wang, PhD
Phone
+8618017316231
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhimin Shao, PhD
Phone
+8618017312288
Email
zhimingshao@yahoo.com
First Name & Middle Initial & Last Name & Degree
Liang Huang, PhD
Phone
+8618121299334
Email
fdhlyx@163.com
Facility Name
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200092
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baosan Han, PhD
Phone
+8618017312288
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310005
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaojia Wang, PhD
Phone
+8613906500190
Facility Name
The First Hospital of Jiaxin
City
Jiaxin
State/Province
Zhejiang
ZIP/Postal Code
314000
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caiping Chen, PhD
Phone
+8613967370819
Facility Name
Lishui Municipal Central Hospital
City
Lishui
State/Province
Zhejiang
ZIP/Postal Code
323020
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shuzheng Chen, PhD
Phone
+8613567618556
Facility Name
Taizhou Central Hospital
City
Taizhou
State/Province
Zhejiang
ZIP/Postal Code
318001
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuechu Dai, PhD
Phone
+8613906768336

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

We'll reach out to this number within 24 hrs